# Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics

> **NCT05674656** · PHASE1,PHASE2 · RECRUITING · sponsor: **ViiV Healthcare** · enrollment: 20 (estimated)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Dolutegravir/Rilpivirine FDC

## Key facts

- **NCT ID:** NCT05674656
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-06
- **Primary completion:** 2026-06-01
- **Final completion:** 2028-05-03
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05674656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05674656, "Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05674656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*